Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

GlobeNewswire August 24, 2022

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

GlobeNewswire August 22, 2022

Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

GlobeNewswire August 19, 2022

Cara Therapeutics Reports Second Quarter 2022 Financial Results

GlobeNewswire August 8, 2022

Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

GlobeNewswire August 3, 2022

Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

GlobeNewswire August 1, 2022

Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

GlobeNewswire June 30, 2022

Cara Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire May 17, 2022

Cara Therapeutics Reports First Quarter 2022 Financial Results

GlobeNewswire May 9, 2022

Cara Therapeutics to Present at May Investor Conferences

GlobeNewswire May 3, 2022

Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

GlobeNewswire April 29, 2022

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

GlobeNewswire April 28, 2022

Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

GlobeNewswire April 5, 2022

Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA(TM) (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

GlobeNewswire April 4, 2022

Cara Therapeutics Announces Oral KORSUVA(TM) (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

GlobeNewswire March 28, 2022

Cara Therapeutics Announces Oral KORSUVA(TM) (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

GlobeNewswire March 8, 2022

Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 1, 2022

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

GlobeNewswire February 25, 2022

Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

GlobeNewswire February 22, 2022